in Florence showed some symptomatic improvement with only minor side effects, but this requires confirmation in a controlled trial. Cyclosporin A does not cause bone marrow depression; but reports of the development of lymphoma in patients treated with the drug after transplantation, 6 and indeed in patients treated with other immunosuppressive drugs,7 mean that immunosuppression should be used circumspectly.
Another approach is based on the finding that suppressor lymphocyte activity is depressed during acute relapses in multiple sclerosis.8 This has raised the possibility of enhancing suppressor cell activity therapeutically, and is yet another potentially promising line of investigation. Probenecid blocks the elimination of the dopamine metabolite homovanillic acid (HVA) from cerebrospinal fluid and can be used to obtain an estimate of dopamine turnover in the central nervous system. Use of this technique'3'4 has produced no evidence of an increase in HVA that could be attributed to overactivity of dopamine neurones. Indeed, within the group of schizophrenic patients poor prognosis'3 and increasing severity of symptoms'4 are associated with decreased concentrations of HVA in the cerebrospinal fluid. Post-mortem studies'5 have also shown no evidence of increased dopamine turnover-a surprising finding, since many patients coming to necropsy have been on long-term medication; presumably (as in animal experiments) the acute effects of neuroleptic drugs on dopamine turnover disappear with continued administration. These studies give no support to the view that dopamine neurones are overactive in schizophrenia (table I) .
By contrast, there is evidence' 156 that the numbers of dopamine receptors are increased in the brains of a proportion (perhaps two-thirds) of patients with schizophrenia, as shown by receptor assay techniques.'5 16 In experiments on animals the numbers of receptors have been found to increase after administration of neuroleptics; but the size of the change (around 100%) in schizophrenic patients is relatively large, and there is an increase in some patients who had been free of medication for the year before death.'5 Moreover, two types of dopamine receptor can be identified by ligand-binding techniques, and only that type of receptor labelled by the butyrophenone antagonist drugs is increased in schizophrenia'7; while receptors labelled by both antagonist and agonist compounds are increased after administration ofneuroleptics. '8 Other neurohumoral theories have been tested in postmortem studies of the brains of schizophrenics. On the basis of the LSD psychosis and the pharmacological antagonism by LSD of some effects of serotonin Gaddum'9 suggested that serotonergic transmission might be deficient. Tryptophan metabolism (by way of the serotonin and other pathways), however, is not abnormal in the schizophrenic brain,2' and serotonin receptors (assessed by binding of LSD and 5-hydroxytryptamine) are unchanged.'7 Reports have been conflicting on possible changes in the monoamine oxidase activity in platelets24 in schizophrenia, but interest in this question has been diminished by the finding25 that enzyme activity, assessed with several different substrates, is normal in the brain of schizophrenics. Finally, there is evidence26 that certain central noradrenergic pathways (such as the locus coeruleus innervation of the cerebral cortex) play a part in reward mechanisms; Stein and Wise27 suggested that these pathways degenerate in schizophrenia. A deficient response to rewarding stimuli is a plausible explanation for some features of the disease, but studies28 of the enzyme dopamine-3-hydroxylase (a marker for noradrenergic neurones) have not shown a consistent reduction in the schizophrenic brain.
At present, therefore, the only change found consistently in the postmortem studies of the schizophrenic brain is an increase in the numbers of dopamine receptors. Since such a change implies an increased and perhaps maladaptive response of the system, this finding could explain the beneficial effects of dopamine antagonists. The Episodes of type I symptoms may be followed by development of the type II syndrome, and both may be present together. Type II symptoms, however, define a group of illnesses of graver prognosis. They occasionally occur in the absence of the type I syndrome (for example, in "simple" schizophrenia), but because these symptoms are not well defined the diagnosis in these cases is difficult to establish.
The cause of schizophrenic illness remains obscure. A genetic influence is undoubted, but the facts that the onset of symptoms is often in adult life and that concordance in monozygotic twins (about 50%/') falls short of 100%1 suggest that genes may be relevant only in predisposing to some other factor. Infection with a slow virus may be relevant.38-40 Some neurotropic viruses (for example, polio, herpes simplex, and zoster) are selective in the cells they attack. Conceivably a slow virus infection might be associated either with a primary chemical disturbance (for example, through an affinity for a receptor site) or with a more general disturbance of higher cognitive functions.
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